ロード中...
Aberrant DNA methylation at HOXA4 and HOXA5 genes are associated with resistance to imatinib mesylate among chronic myeloid leukemia patients
BACKGROUND: Imatinib mesylate is a molecularly targeted tyrosine kinase inhibitor drug. It is effectively used in the treatment of chronic myeloid leukemia (CML) patients. However, development of resistance to imatinib mesylate as a result of BCR‐ABL dependent and BCR‐ABL independent mechanisms has...
保存先:
| 出版年: | Cancer Rep (Hoboken) |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7941502/ https://ncbi.nlm.nih.gov/pubmed/32721103 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cnr2.1111 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|